TABLE 2.
Annual Price, $a | Cost per QALY, $ | |
---|---|---|
Omalizumab | 28,900 | 325,000 |
Mepolizumab | 29,500 | 344,000 |
Reslizumab | 28,900 | 391,000 |
Benralizumab | 27,800 | 371,000 |
Dupilumab | 31,000 | 351,000 |
aAverage annual price of each treatment, net of discounts and rebates, as reported to ICER by each manufacturer.
ICER = Institute for Clinical and Economic Review; QALY = quality-adjusted life-year.